Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) - Research analysts at HC Wainwright lifted their FY2024 EPS estimates for shares of Olema Pharmaceuticals in a report issued on Wednesday, December 11th. HC Wainwright analyst E. Bodnar now forecasts that the company will earn ($2.23) per share for the year, up from their prior estimate of ($2.34). HC Wainwright has a "Buy" rating and a $30.00 price target on the stock. The consensus estimate for Olema Pharmaceuticals' current full-year earnings is ($2.35) per share. HC Wainwright also issued estimates for Olema Pharmaceuticals' Q4 2024 earnings at ($0.53) EPS, Q1 2025 earnings at ($0.64) EPS, Q2 2025 earnings at ($0.76) EPS, Q3 2025 earnings at ($0.89) EPS, Q4 2025 earnings at ($0.97) EPS, FY2025 earnings at ($3.25) EPS, FY2026 earnings at ($4.14) EPS, FY2027 earnings at ($3.84) EPS and FY2028 earnings at ($3.28) EPS.
Olema Pharmaceuticals Trading Up 0.4 %
OLMA stock traded up $0.03 during midday trading on Friday, hitting $6.75. 2,674,129 shares of the company's stock were exchanged, compared to its average volume of 757,673. The firm has a 50 day moving average price of $10.70 and a 200-day moving average price of $11.86. Olema Pharmaceuticals has a 12-month low of $6.24 and a 12-month high of $16.77. The stock has a market capitalization of $386.78 million, a price-to-earnings ratio of -3.08 and a beta of 1.92.
Insider Activity
In other Olema Pharmaceuticals news, Director Cyrus Harmon sold 8,256 shares of the firm's stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $9.37, for a total value of $77,358.72. Following the sale, the director now owns 772,277 shares in the company, valued at approximately $7,236,235.49. This trade represents a 1.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Sean Bohen sold 52,328 shares of the stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $9.37, for a total value of $490,313.36. Following the completion of the transaction, the chief executive officer now directly owns 298,836 shares of the company's stock, valued at approximately $2,800,093.32. The trade was a 14.90 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 73,036 shares of company stock worth $684,472. 19.40% of the stock is currently owned by insiders.
Institutional Investors Weigh In On Olema Pharmaceuticals
A number of institutional investors and hedge funds have recently modified their holdings of OLMA. Ensign Peak Advisors Inc raised its stake in Olema Pharmaceuticals by 6.1% during the 2nd quarter. Ensign Peak Advisors Inc now owns 14,849 shares of the company's stock valued at $161,000 after purchasing an additional 850 shares during the period. California State Teachers Retirement System raised its position in Olema Pharmaceuticals by 3.4% during the first quarter. California State Teachers Retirement System now owns 34,695 shares of the company's stock valued at $393,000 after buying an additional 1,132 shares during the period. Price T Rowe Associates Inc. MD raised its position in Olema Pharmaceuticals by 6.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 26,251 shares of the company's stock valued at $298,000 after buying an additional 1,486 shares during the period. ClariVest Asset Management LLC lifted its stake in Olema Pharmaceuticals by 3.1% in the 2nd quarter. ClariVest Asset Management LLC now owns 63,149 shares of the company's stock worth $683,000 after acquiring an additional 1,881 shares in the last quarter. Finally, EP Wealth Advisors LLC boosted its position in Olema Pharmaceuticals by 5.2% during the 3rd quarter. EP Wealth Advisors LLC now owns 48,655 shares of the company's stock worth $581,000 after acquiring an additional 2,407 shares during the period. Institutional investors and hedge funds own 91.78% of the company's stock.
Olema Pharmaceuticals Company Profile
(
Get Free Report)
Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.
Further Reading
Before you consider Olema Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Olema Pharmaceuticals wasn't on the list.
While Olema Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
